ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification of Epigenetic Biomarkers Allowing to Predict the Evolution of Lung Disease Severity in Cystic Fibrosis, in Order to Improve Patient Follow-up and to Move Toward Personalized Medicine (MethylBiomark)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02976714
Recruitment Status : Recruiting
First Posted : November 29, 2016
Last Update Posted : May 12, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2018
  Estimated Study Completion Date : May 2019